Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.

CONCLUSIONS: Results confirm that adverse events 3 days after vaccination with the rVSV candidate vaccine are common. The occurrence of fever is of particular concern in the context of ongoing Ebola transmission. Additional studies should address important data gaps regarding the use of the vaccine in pregnancy and other vulnerable populations.
PMID: 30266489 [PubMed - as supplied by publisher]

Source: Vaccine - September 25, 2018 Category: Allergy & Immunology Authors: Juan-Giner A, Tchaton M, Jemmy JP, Soumah A, Boum Y, Faga EM, Cisse M, Grais RF Tags: Vaccine Source Type: research